Pharming Group N.V. (PHARM.AS)
EUR 0.8
(-3.32%)
EUR 0.8
(-3.32%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 228.28 Million EUR | 3.22% |
| 2022 | 221.15 Million USD | 8.31% |
| 2021 | 204.18 Million EUR | -13.26% |
| 2020 | 235.38 Million EUR | 70.11% |
| 2019 | 138.37 Million EUR | -20.84% |
| 2018 | 174.8 Million EUR | -1.14% |
| 2017 | 176.82 Million EUR | 69.29% |
| 2016 | 104.45 Million EUR | 182.34% |
| 2015 | 36.99 Million EUR | 17.58% |
| 2014 | 31.46 Million EUR | -13.68% |
| 2013 | 36.45 Million EUR | 12.52% |
| 2012 | 32.39 Million EUR | -3.43% |
| 2011 | 33.54 Million EUR | -7.23% |
| 2010 | 36.15 Million EUR | -40.72% |
| 2009 | 60.99 Million EUR | -19.7% |
| 2008 | 75.95 Million EUR | -34.6% |
| 2007 | 116.14 Million EUR | 200.99% |
| 2006 | 38.58 Million EUR | 457.08% |
| 2005 | 6.92 Million EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 194.99 Million EUR | -12.57% |
| 2024 Q3 | 199.72 Million USD | -3.09% |
| 2024 Q1 | 235.72 Million USD | -6.52% |
| 2023 FY | 228.28 Million EUR | 3.22% |
| 2023 Q4 | 244.07 Million USD | 7.75% |
| 2023 Q3 | 226.52 Million USD | -1.27% |
| 2023 Q2 | 229.43 Million USD | 2.58% |
| 2023 Q1 | 223.65 Million USD | 1.13% |
| 2022 Q4 | 221.15 Million USD | 21.47% |
| 2022 Q2 | 194.22 Million USD | -2.29% |
| 2022 Q3 | 182.06 Million USD | -6.26% |
| 2022 FY | 221.15 Million USD | 8.31% |
| 2022 Q1 | 198.77 Million USD | 10.22% |
| 2021 Q2 | 213.86 Million EUR | -3.9% |
| 2021 FY | 204.18 Million EUR | -13.26% |
| 2021 Q3 | 207.37 Million EUR | -3.03% |
| 2021 Q4 | 180.34 Million EUR | -13.04% |
| 2021 Q1 | 222.53 Million EUR | -5.46% |
| 2020 FY | 235.38 Million EUR | 70.11% |
| 2020 Q1 | 207.69 Million EUR | 50.1% |
| 2020 Q2 | 213.17 Million EUR | 2.64% |
| 2020 Q3 | 214.96 Million EUR | 0.84% |
| 2020 Q4 | 235.38 Million EUR | 9.5% |
| 2019 Q4 | 138.37 Million EUR | -2.97% |
| 2019 Q3 | 142.6 Million EUR | -2.25% |
| 2019 FY | 138.37 Million EUR | -20.84% |
| 2019 Q2 | 145.88 Million EUR | -0.45% |
| 2019 Q1 | 146.54 Million EUR | -16.17% |
| 2018 Q2 | 162.68 Million EUR | -5.12% |
| 2018 Q3 | 167.95 Million EUR | 3.25% |
| 2018 FY | 174.8 Million EUR | -1.14% |
| 2018 Q4 | 174.8 Million EUR | 4.08% |
| 2018 Q1 | 171.46 Million EUR | -3.03% |
| 2017 Q1 | 109.53 Million EUR | 4.86% |
| 2017 FY | 176.82 Million EUR | 69.29% |
| 2017 Q4 | 176.82 Million EUR | 12.6% |
| 2017 Q3 | 157.03 Million EUR | 14.21% |
| 2017 Q2 | 137.5 Million EUR | 25.54% |
| 2016 FY | 104.45 Million EUR | 182.34% |
| 2016 Q1 | 39.37 Million EUR | 6.42% |
| 2016 Q4 | 104.45 Million EUR | 174.84% |
| 2016 Q2 | 39.5 Million EUR | 0.33% |
| 2016 Q3 | 38 Million EUR | -3.79% |
| 2015 Q3 | 41.16 Million EUR | 64.82% |
| 2015 Q1 | 26.5 Million EUR | -15.75% |
| 2015 FY | 36.99 Million EUR | 17.58% |
| 2015 Q2 | 24.97 Million EUR | -5.79% |
| 2015 Q4 | 36.99 Million EUR | -10.13% |
| 2014 Q3 | 31.57 Million EUR | -19.66% |
| 2014 FY | 31.46 Million EUR | -13.68% |
| 2014 Q2 | 39.29 Million EUR | 9.51% |
| 2014 Q4 | 31.46 Million EUR | -0.34% |
| 2014 Q1 | 35.88 Million EUR | -1.56% |
| 2013 Q2 | 38.14 Million EUR | -15.91% |
| 2013 FY | 36.45 Million EUR | 12.52% |
| 2013 Q4 | 36.45 Million EUR | 6.73% |
| 2013 Q3 | 34.15 Million EUR | -10.46% |
| 2013 Q1 | 45.36 Million EUR | 40.02% |
| 2012 Q4 | 32.39 Million EUR | -5.72% |
| 2012 Q1 | 41.69 Million EUR | 24.29% |
| 2012 FY | 32.39 Million EUR | -3.43% |
| 2012 Q3 | 34.36 Million EUR | 0.0% |
| 2011 Q2 | 37.21 Million EUR | 7.17% |
| 2011 Q1 | 34.72 Million EUR | -3.97% |
| 2011 Q3 | 34.68 Million EUR | -6.79% |
| 2011 Q4 | 33.54 Million EUR | -3.29% |
| 2011 FY | 33.54 Million EUR | -7.23% |
| 2010 Q3 | 49.63 Million EUR | -32.94% |
| 2010 FY | 36.15 Million EUR | -40.72% |
| 2010 Q4 | 36.15 Million EUR | -27.15% |
| 2010 Q2 | 74 Million EUR | -0.76% |
| 2010 Q1 | 74.57 Million EUR | 22.27% |
| 2009 FY | 60.99 Million EUR | -19.7% |
| 2009 Q4 | 60.99 Million EUR | 0.0% |
| 2008 FY | 75.95 Million EUR | -34.6% |
| 2007 FY | 116.14 Million EUR | 200.99% |
| 2006 FY | 38.58 Million EUR | 457.08% |
| 2005 FY | 6.92 Million EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| ABIONYX Pharma SA | 6.91 Million EUR | -3202.734% |
| ABIVAX Société Anonyme | 131.05 Million EUR | -74.194% |
| Adocia SA | 31.87 Million EUR | -616.301% |
| Aelis Farma SA | 13.08 Million EUR | -1645.298% |
| Biophytis S.A. | 15.84 Million EUR | -1340.375% |
| Advicenne S.A. | 24.37 Million EUR | -836.477% |
| genOway Société anonyme | 14.45 Million EUR | -1478.787% |
| IntegraGen SA | 5.97 Million EUR | -3717.604% |
| Medesis Pharma S.A. | 6.42 Million EUR | -3452.419% |
| Neovacs S.A. | 3.71 Million EUR | -6049.713% |
| NFL Biosciences SA | 3.62 Million EUR | -6205.025% |
| Plant Advanced Technologies SA | 6.78 Million EUR | -3265.867% |
| Quantum Genomics Société Anonyme | 3.31 Million EUR | -6796.604% |
| Sensorion SA | 13.22 Million EUR | -1625.866% |
| Theranexus Société Anonyme | 5.01 Million EUR | -4450.964% |
| TME Pharma N.V. | 2.78 Million EUR | -8096.947% |
| Valbiotis SA | 13.7 Million EUR | -1565.341% |
| TheraVet SA | 1.48 Million EUR | -15272.798% |
| Valerio Therapeutics Société anonyme | 20.46 Million EUR | -1015.326% |
| argenx SE | 402.79 Million EUR | 43.325% |
| BioSenic S.A. | 32.26 Million EUR | -607.553% |
| Celyad Oncology SA | 9.97 Million EUR | -2187.883% |
| DBV Technologies S.A. | 38.74 Million USD | -489.194% |
| Galapagos NV | 1.56 Billion EUR | 85.383% |
| Genfit S.A. | 105.92 Million EUR | -115.524% |
| GeNeuro SA | 20.13 Million EUR | -1033.496% |
| Hyloris Pharmaceuticals SA | 8.61 Million EUR | -2550.778% |
| Innate Pharma S.A. | 132.29 Million EUR | -72.561% |
| Inventiva S.A. | 101.59 Million EUR | -124.705% |
| MaaT Pharma SA | 22.46 Million EUR | -916.181% |
| MedinCell S.A. | 77.77 Million EUR | -193.539% |
| Nanobiotix S.A. | 95.74 Million EUR | -138.443% |
| Onward Medical N.V. | 25.69 Million EUR | -788.338% |
| Oryzon Genomics S.A. | 25.12 Million EUR | -808.579% |
| OSE Immunotherapeutics SA | 59.07 Million EUR | -286.406% |
| Oxurion NV | 19.73 Million EUR | -1056.693% |
| Poxel S.A. | 53.9 Million EUR | -323.526% |
| GenSight Biologics S.A. | 34.72 Million EUR | -557.37% |
| Transgene SA | 26.51 Million EUR | -760.9% |
| Financière de Tubize SA | 123.65 Million EUR | -84.622% |
| UCB SA | 6.56 Billion EUR | 96.522% |
| Valneva SE | 341.14 Million EUR | 33.083% |
| Vivoryon Therapeutics N.V. | 4.54 Million EUR | -4920.563% |